3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
4
Breast
3
Thoracic
2
Sarcoma
2
Tumor-Agnostic
1
Plasma cell
1
Other solid neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Sarcoma
2
Sarcoma, Synovial
1
Liposarcoma
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Dermatofibrosarcoma
1
Bone Neoplasms
1
Interventions
Cyclophosphamide
54
Specimen Handling
50
Magnetic Resonance Spectroscopy
49
pembrolizumab
43
Doxorubicin
43
Radiotherapy
42
Temozolomide
37
Biopsy
34
Radiation
29
Nivolumab
28
fludarabine
23
Vincristine
22
Irinotecan
21
Gemcitabine
21
X-Rays
20
Surgical Procedures, Operative
19
Ifosfamide
19
atezolizumab
17
cabozantinib
15
Ipilimumab
15
olaparib
13
Sunitinib
13
Paclitaxel
13
regorafenib
12
fludarabine phosphate
12
Phantoms, Imaging
12
Imatinib Mesylate
12
Etoposide
12
Blood Specimen Collection
12
Carboplatin
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Quality of Life
×
Sarcoma
×
1 year
×
Clear all
NCT05051059
2026-03-16
QOLSarcoma
Universitaire Ziekenhuizen KU Leuven
Phase NA
Recruiting
60 enrolled
NCT07169344
2026-01-28
PROSARC-1
Oslo University Hospital
Phase 2
Recruiting
110 enrolled